Rein Therapeutics
RNTX
22 hedge funds and large institutions have $5.2M invested in Rein Therapeutics in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
4% less funds holding
Funds holding: 23 → 22 (-1)
16.17% less ownership
Funds ownership: 43.24% → 27.07% (-16%)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
58% less capital invested
Capital invested by funds: $12.3M → $5.2M (-$7.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.68M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.33M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$316K |
| 4 |
Renaissance Technologies
New York
|
+$69.8K |
| 5 |
BlackRock
New York
|
+$41.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.67M |
| 2 |
Morgan Stanley
New York
|
-$483K |
| 3 |
Bank of New York Mellon
New York
|
-$155K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$110K |
| 5 |
BAM
Brave Asset Management
Summit,
New Jersey
|
-$32K |
RNTX Hedge Fund Activity: Q2 2019 in Review
22 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2019, worth a combined $5.2M — down 58% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RNTX and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $2.68M. The largest seller was Armistice Capital, cutting an estimated $2.67M.
- 22 institutional investors held Rein Therapeutics (RNTX) as of Q2 2019, down from 23 in Q1 2019.
- Funds reported $5.2M of Rein Therapeutics stock for Q2 2019, down 58% quarter-over-quarter.
- 4 funds opened new Rein Therapeutics positions in Q2 2019 and 5 closed out, a net change of -1 holder.
- The largest Rein Therapeutics buyer in Q2 2019 was Baker Bros. Advisors, an estimated $2.68M added.
- The largest Rein Therapeutics seller in Q2 2019 was Armistice Capital, an estimated $2.67M sold.
Based on aggregated 13F filings for Q2 2019.